GlaxoSmithKline Sell Rating Justified by Arexvy Underperformance and Reduced Revenue Projections
GSK Says Health Canada Approves Jemperli as Endometrial Cancer Treatment
GlaxoSmithKline (GSK) Receives a Buy From Jefferies
Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial
Viiv's Dovato as Effective as Gilead' Biktarvy for HIV but With Less Weight Gain
ViiV Healthcare Announces Positive Data Demonstrating 2-drug Regimen Dovato Is as Effective as 3-drug Regimen Biktarvy for Maintenance Therapy of HIV-1
ViiV Healthcare Announces Positive New Data for Apretude Use During Pregnancy at AIDS 2024
ViiV Healthcare Premieres Early Data Showing Antiviral Activity Against Integrase Resistance From Its Investigational, Third-generation Integrase Inhibitor
Here Are Big Pharma's Leading Blockbuster Makers
GSK's Marketing Authorization Application for Blenrep Combinations Accepted for Review in EU
Blenrep (Belantamab Mafodotin) Combinations in Multiple Myeloma Application Accepted for Review by the European Medicines Agency
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading
Global Drug Discovery Technologies Market Insights, 2024-2033 - Top 10 Companies Account for 26.61% of the Total Market; AstraZeneca Leads With 5.73% Share, Followed by Merck and GlaxoSmithKline
Unusual Options Activity: GOOG, BKR and Others Attract Market Bets, GOOG V/OI Ratio Reaches 357.1
GSK to Deliver Over 36M Flu Shots for Fall Immunization Drive
GSK Begins Shipping Influenza Vaccine Doses for 2024-25 Season
Is GSK an Attractive Drug Stock to Add to Your Portfolio Now?
GlaxoSmithKline (GSK) Receives a Buy From Deutsche Numis
GSK Plc (GSK): Is It the Best FTSE Dividend Stock to Buy According to Hedge Funds?
GSK Cut to Neutral From Buy by UBS